Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Thursday, September 8, 2016

Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double blind and controlled clinical trial

You will have to hire a researcher to complete testing in stroke survivors, otherwise it will never get done. Basically blood doping like athletes do illegally. More red blood cells sounds like something useful immediately post-stroke. Don't do this on your own.
Blood doping is a method of increasing athletic performance by artificially increasing an athlete's red blood cell (RBC) count. Because red blood cells carry oxygen to the muscles, having a higher RBC count can dramatically improve an athlete's aerobic capacity and delay fatigue.
Choose an option to locate/access this article:
Check if you have access through your login credentials or your institution
Check access


EPO treatment following severe traumatic brain injury improves functional recovery.
EPO treatment decreases serum neuron specific enolase and S-100β protein.
EPO treatment is not associated with thromboembolic events or severe infections.



To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury.


One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n = 79) and control group (n = 80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment. Serum neuron specific enolase (NSE) and S-100β protein were measured within the first three months after treatment.


In the end, 146 patients (75 of the EPO group and 71 of the control group) completed the trial. Three months after the treatment, Good recovery was found in 33.3% of the EPO and 12.6% of the control group patients (p < 0.05). Serum NSE and S-100β protein were decreased gradually in both groups after treatment, but their levels in the EPO group were lower than that of control group (p < 0.05). There was no statistically significant difference in blood pressure, hemoglobin levels, pneumonia, sepsis or thromboembolic events between the two groups three months after the treatment (p > 0.05).


Treatment with five doses of recombinant human erythropoietin is associated with an improved functional recovery in patients with severe traumatic brain injury. This treatment does not seem to increase the risk of thromboembolic events or severe infections.

No comments:

Post a Comment